A Randomized Phase II/III Study of TNFerade TM Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer.
Phase of Trial: Phase III
Latest Information Update: 22 Jan 2013
At a glance
- Drugs Golnerminogene pradenovec (Primary) ; Fluorouracil; Gemcitabine
- Indications Pancreatic cancer
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms PACT
- Sponsors GenVec
- 22 Jan 2013 Final results published in the Journal of Clinical Oncology.
- 04 Jun 2012 Primary endpoint 'Overall-survival' has not been met.
- 04 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History